Vertex's HCV Drug Might Gain Advantage Over Merck's From FDA Draft Guidance
FDA’s draft guidance on chronic hepatitis C drug development inspired one analyst to predict an advantage for Vertex Pharmaceuticals’ telaprevir over Merck & Co.’s boceprevir.
You may also be interested in...
Collective top-line data from the Phase III program testing Vertex Pharmaceuticals' protease inhibitor telaprevir in treatment-naïve and treatment-experienced hepatitis C patients set a high bar for competitors, particularly for Merck & Co.'s boceprevir, with which telaprevir is dueling to be the first approved specifically targeted antiviral therapy for hepatitis C (STAT-C).
Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies, the agency’s policy for using background music in direct-to-consumer advertising, and the FDA’s new incoming principal deputy commissioner.
A recent externally-led PFDD meeting on kidney xenotransplantation, rather than a specific disease, allowed for more tailored patient comments on the procedure, which could impact development plans going forward.